Glepaglutide

Summary

Glepaglutide (CHEMBL4297761) is a phase-3 clinical-stage protein; indicated across 3 conditions including short bowel syndrome and crohn disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 3 conditions
• Clinical trials: 11

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297761
Name	Glepaglutide
Type	Protein
Max phase	3

Also known as: Glepaglutida, Glepaglutide, ZP-1848, Zp1848, ZP1848, GLEPAGLUTIDE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
short bowel syndrome	3	MONDO:0015183	MONDO:0015183
Crohn disease	1	MONDO:0005011	EFO:0000384
kidney disorder	1	MONDO:0005240	EFO:0003086

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE3	6
PHASE1	4
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03905707	PHASE3	ACTIVE_NOT_RECRUITING	Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
NCT04881825	PHASE3	ACTIVE_NOT_RECRUITING	Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial
NCT07197944	PHASE3	RECRUITING	Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
NCT07228403	PHASE3	ENROLLING_BY_INVITATION	Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome
NCT03690206	PHASE3	COMPLETED	Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)
NCT04991311	PHASE3	COMPLETED	The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome
NCT02690025	PHASE2	COMPLETED	A Phase 2 Trial Testing ZP1848 in Patients With SBS
NCT00868660	PHASE1	COMPLETED	Healthy Normal Single Ascending Dose and Crohn’s Patient Multiple Ascending Dose
NCT03279302	PHASE1	COMPLETED	Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects
NCT04178447	PHASE1	COMPLETED	Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal Function
NCT04318743	PHASE1	COMPLETED	A Bridging Trial to Compare the PK Profile When Glepaglutide is Administered Via Vial/Syringe Versus Autoinjector.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).